RxDoctor Payments Data

Karl Vogelbach, MD

Cardiovascular Disease · Arcadia, CANPI 1487611638

Payments from drug & device makers

$118,058in general payments, 2019–2025

Across 634 payments — averaging $186.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$78K
  • Amgen$30K
  • Novartis$1K
  • Bayer$911
  • Merck$904
  • Amarin Pharma, Inc.$901
  • plus $6K from 30 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$100,52585%
  • Travel & lodging$1,9382%
  • Food & beverage$15,14613%
  • Education$1490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,058 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$484,876
Medicare patients
1,167
Services billed
3,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban437$471,938
EntrestoSacubitril/Valsartan167$176,952
JardianceEmpagliflozin148$158,240
EliquisApixaban51$66,085
OzempicSemaglutide39$57,851
VascepaIcosapent Ethyl86$50,900
Repatha SureclickEvolocumab58$44,798
FarxigaDapagliflozin Propanediol39$37,660
Repatha PushtronexEvolocumab55$35,970
VerquvoVericiguat26$35,223
EdarbyclorAzilsartan Med/Chlorthalidone46$22,821
NexlizetBempedoic Acid/Ezetimibe17$17,230
Icosapent Ethyl35$14,056
EdarbiAzilsartan Medoxomil25$10,807
Ezetimibe297$8,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$78,103$471,938437 claims
NovartisEntresto$1,270$176,952167 claims
Boehringer IngelheimJardiance$814$158,240148 claims
PfizerEliquis$298$66,08551 claims
Novo NordiskOzempic$314$57,85139 claims
AstraZenecaFarxiga, Crestor$667$41,44651 claims
MerckVerquvo$904$35,22326 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$166$33,62871 claims
Esperion Therapeutics, Inc.Nexlizet$790$17,23017 claims
AmgenCorlanor$29,518$5,82815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →